Novo Nordisk partners with Taiwan’s Health2Sync to bring its diabetes management app to Japan

phone texting
Health2Sync's app tracks blood sugar trends and reminds users to adhere to meal, exercise and glucose management plans. (Pixabay)

Novo Nordisk has partnered with Taiwan-based Health2Sync to help promote the latter’s digital diabetes management app in Japan.

Last December, the two companies began localization efforts for the SyncHealth app, known as Health2Sync outside of Japan, as well as its web platform for patient management and communication with healthcare providers.

The app tracks blood sugar trends and the effectiveness of treatments through a behavior-focused artificial intelligence engine and reminds users to adhere to meal, exercise and glucose management plans.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Novo Nordisk will support the distribution and adoption of the app and healthcare provider platform in Japan, while Health2Sync will be responsible for preserving and processing patient data.

RELATED: Taiwanese diabetes management startup raises $3M for overseas expansion

In the future, Novo Nordisk aims to wirelessly connect its insulin delivery devices with the app, including an upcoming smart insulin pen, to enable automatic data recording of self-injected drugs.

The Big Pharma has been working to make sure its connected insulin pens are compatible with other diabetes-focused hardware and software on the market through nonexclusive partnerships—including Abbott’s Freestyle Libre line of digital health tools and continuous glucose monitoring devices, as well as Glooko’s cloud platform.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.